FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Degnan Chris					2. Issuer Name and Ticker or Trading Symbol Verrica Pharmaceuticals Inc. [VRCA]									5. Relationship of Reporting Pe (Check all applicable) Director				10% O	wner
(Last)	(Fi	rst) (	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/28/2019								X	Office below	er (give title v)		Other (specify below)	
C/O VERRICA PHARMACEUTICALS INC.														Chief Financial Officer					
10 NORTH HIGH STREET, SUITE 200				4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)															X Form filed by One Reporting Person				
WEST CHESTE	ER PA	A 1	19380												Form Perso	•	led by More than One Rep		orting
(City)	(Si	ate) (	Zip)																
		Tab	le I - No	n-Deriv	ative S	Sec	urities	Ac	quired, E	isp	osed o	of, or Be	enefic	ially	Owne	d			
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)					·	Execution Date,			Code (In	Transaction Disposed Code (Instr. and 5)		rities Acquired ( ed Of (D) (Instr. 3		, 4 Securi Benefi Owned		ties Fo cially (D)		m: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	٧	Amoun	nt (A) or (D)		ce				tr. 4)	(Instr. 4)
		T						•	uired, Dis	•				•	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		n of E		Expiration	6. Date Exercisable and Expiration Date Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Price erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
					Code	v	(A)	(D)	Date Exercisable		piration ite	Title	Amous or Number of Shares	er					
Employee Stock Option (Right to Buy)	\$11.32	02/28/2019			A		44,000		(1)	02	/27/2029	Common Stock	44,00	00	\$0.00	44,000		D	

## Explanation of Responses:

1, 25% of shares subject to the option shall vest on February 28, 2020 (the "Initial Vesting Date"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Initial Vesting Date, subject to the Reporting Person continuing to be a service provider through each such date.

## Remarks:

/s/ Mark Ballantyne, Attorneyin-Fact 03/04/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.